Strong data on Erbitux in novel combos to be presented at ASCO

17 May 2009

Studies to be presented at the forthcoming American Society of Clinical Oncology meeting in Orlando, Florida, at the end of the month, show that  German drugmaker Merck Serono's leading oncology product Erbitux  (cetuximab), when added to standard chemotherapy or radiotherapy  regimens, significantly improves treatment efficacy in metastatic  colorectal cancer, squamous cell carcinoma of the head and neck and  non-small cell lung cancer, without significantly affecting overall  quality of life.

Other study findings at ASCO will highlight Erbitux' potential in a  number of new cancer types, such as gastric and biliary, in combination  with a range of different standard chemotherapy and radiotherapy  regimens.

Erbitux in combination with irinotecan/5-fluorouracil/folinic acid for  the first-line treatment of advanced gastric cancer was well tolerated  with encouraging survival data. This novel combination regimen yielded  an overall tumor response rate of 42%, with median progression-free  survival and overall survival times of 8.5 and 16.6 months,  respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight